How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.

Mark Rukavina joins Ethics Talk to discuss how consumer advocacy groups can help advance health justice and equity.

Dr Lisa Lehmann joins Ethics Talk to discuss “grateful patient programs,” pressures clinicians face to fundraise on behalf of health care organizations for which they work, and whether “VIP” care really is better for patients.

Dr Ziad Obermeyer talks about the potential impact on mortality of cost-sharing practices of health insurers.

In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013.

Standard treatment of hyperglycemia in type 2 diabetes includes a pathway when “cost is a major issue.” Whether it’s just to do so remains unclear.

A paradigm shift in circadian science is underway, exposing ethical tensions from a legacy of pervasive neglect of circadian disorders.

Capital and staff shortages have forced many rural hospitals to close. Private equity investment in rural hospitals has been one solution to these problems.

Poor-quality antimicrobial medicines continue to proliferate across supply chains, threatening patients’ health and safety, especially in low- and middle-income regions.

MLPs in the VHA help minimize ethical tensions that tend to come up when diagnosing and documenting disability.